...Duke University licensed Opara’s porcine β cell encapsulation technology in 1998 to MicroIslet Inc., now Islet Sciences Inc....
...encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure.” Nature Communications (2017) Allison Johnson, Staff Writer Islet Sciences Inc. MicroIslet...

...from Kissei (see BioCentury, Jan. 10, 2011). BHV Pharma Inc. , Research Triangle Park, N.C. Islet Sciences Inc....

...Nagano, Japan) (see BioCentury, Jan. 10, 2011). BHV Pharma Inc. , Research Triangle Park, N.C. Islet Sciences Inc....

...BHV will receive a percentage of either net sales or net profit in Libbs' territories. Islet Sciences Inc....

...BHV and Islet Sciences Inc. (OTCBB:ISLT, New York, N.Y.) reported data from a pair of double-blind, dose-ranging, placebo...
...presented at the American Diabetes Association meeting in San Francisco in June. Additionally, BHV and Islet Sciences...
...dosing limiting the undesirable effects of nighttime inhibition of SGLT2. As a result, BHV and Islet Sciences...

...BHV Pharma Inc. (Research Triangle Park, N.C.) and Islet Sciences Inc. (OTCBB:ISLT) reported data on Wednesday from a...
...both trials will be presented at the American Diabetes Association meeting in June. BHV and Islet Sciences...
...remogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Last month, Islet Sciences...

...BHV shareholders 30 million shares of Islet Sciences common stock, valued at $12 million based on Islet Sciences'...
...million in additional shares to BHV shareholders based on milestones related to BHV's remogliflozin etabonate. Islet Sciences...
...Type I diabetes and insulin-dependent Type II diabetes. Neither company has reported revenue. Last November, Islet Sciences...